Literature DB >> 20072850

Proteolytically inactive per a 10 allergen of Periplaneta americana modulates Th2 response and enhances IL-10 in mouse model.

Deepsikha Srivastava1, Amit Kumar Mehta, Naveen Arora, Shailendra Nath Gaur, Bhanu Pratap Singh.   

Abstract

BACKGROUND: Purified allergens with reduced IgE reactivity are required to improve the safety and efficacy of allergen-specific immunotherapy (IT).
OBJECTIVE: The present study investigates the efficacy of purified cockroach allergen immunotherapy with proteolytically active and inactive Per a 10 in allergic mouse model.
METHODS: Balb/c mice were sensitized intraperitoneally with cockroach extract (CE) and purified allergen Per a 10 in separate groups. Mice were treated subcutaneously with phosphate-buffered saline (PBS), CE, active and inactive Per a 10 and challenged intranasally. Antigen specific IgE, IgG1 and IgG2a in serum and cytokines IL-4, IL-13, IFN-gamma, IL-10, TGF-beta in bronchoalveolar lavage (BAL) fluid and spleen culture supernatant (CS) were estimated by enzyme-linked immunosorbent assay. Lung histology was analyzed by hematoxylin and eosin staining.
RESULTS: IT with Per a 10 demonstrated significant reduction in IgE levels in serum, IL-4 levels in BAL fluid, CS, and eosinophilic infiltration in lungs than PBS-treated mice. This was associated with significantly increased IL-10 secretion in BAL fluid and CS. IT with Per a 10 effectively suppressed T-helper type 2 (Th2) response in mice sensitized with Per a 10 than CE group. Further, IT with inactive Per a 10 showed maximum reduction in systemic and airway inflammation and induced maximum IL-10 release in BAL fluid and CS than other antigens.
CONCLUSIONS: IT with Per a 10 effectively suppressed Th2 response and lung inflammation in Per a 10- or CE-sensitized mice. The beneficial effects of IT with inactive Per a 10 are more pronounced than active Per a 10.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20072850     DOI: 10.1007/s10875-009-9362-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  46 in total

1.  Asthma and allergy - a global perspective.

Authors:  E D Bateman; A Jithoo
Journal:  Allergy       Date:  2007-03       Impact factor: 13.146

Review 2.  Component-resolved diagnosis to optimize allergen-specific immunotherapy in the Mediterranean area.

Authors:  R Valenta; T Twaroch; I Swoboda
Journal:  J Investig Allergol Clin Immunol       Date:  2007       Impact factor: 4.333

3.  Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials.

Authors:  M J Abramson; R M Puy; J M Weiner
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

4.  The role of immunotherapy in cockroach asthma.

Authors:  B C Kang; J Johnson; C Morgan; J L Chang
Journal:  J Asthma       Date:  1988       Impact factor: 2.515

Review 5.  Recombinant marker allergens: diagnostic gatekeepers for the treatment of allergy.

Authors:  Lili Kazemi-Shirazi; Verena Niederberger; Birgit Linhart; Jonas Lidholm; Dietrich Kraft; Rudolf Valenta
Journal:  Int Arch Allergy Immunol       Date:  2002-04       Impact factor: 2.749

6.  Induction of T-helper type 2 cytokine release and up-regulated expression of protease-activated receptors on mast cells by recombinant American cockroach allergen Per a 7.

Authors:  Z Zhang; H Zhang; H Yang; L Zhang; X Chen; X Zheng; S He
Journal:  Clin Exp Allergy       Date:  2008-07       Impact factor: 5.018

7.  Role of interleukin 10 in specific immunotherapy.

Authors:  C A Akdis; T Blesken; M Akdis; B Wüthrich; K Blaser
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

8.  Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation.

Authors:  Alain Razafindratsita; Nathalie Saint-Lu; Laurent Mascarell; Nathalie Berjont; Thierry Bardon; Didier Betbeder; Laurence Van Overtvelt; Philippe Moingeon
Journal:  J Allergy Clin Immunol       Date:  2007-05-25       Impact factor: 10.793

9.  IL-4 is required to generate and sustain in vivo IgE responses.

Authors:  F D Finkelman; I M Katona; J F Urban; J Holmes; J Ohara; A S Tung; J V Sample; W E Paul
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

10.  Differences in IL-4 release by PBMC are related with heterogeneity of atopy.

Authors:  J Pène; A Rivier; B Lagier; W M Becker; F B Michel; J Bousquet
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

View more
  6 in total

1.  Characterization of recombinant per a 10 from Periplaneta americana.

Authors:  Dhanapal Govindaraj; Shailendra Nath Gaur; Naveen Arora
Journal:  Clin Vaccine Immunol       Date:  2012-12-19

2.  Immunotherapy with B cell epitopes ameliorates inflammatory responses in Balb/c mice.

Authors:  P Sharma; S N Gaur; N Arora
Journal:  Clin Exp Immunol       Date:  2015-01       Impact factor: 4.330

3.  Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy.

Authors:  Tanveer Ahmad; Shravani Mukherjee; Bijay Pattnaik; Manish Kumar; Suchita Singh; Manish Kumar; Rakhshinda Rehman; Brijendra K Tiwari; Kumar A Jha; Amruta P Barhanpurkar; Mohan R Wani; Soumya S Roy; Ulaganathan Mabalirajan; Balaram Ghosh; Anurag Agrawal
Journal:  EMBO J       Date:  2014-01-15       Impact factor: 11.598

4.  Per a 10 protease activity modulates CD40 expression on dendritic cell surface by nuclear factor-kappaB pathway.

Authors:  C Goel; N Kalra; B S Dwarakanath; S N Gaur; N Arora
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

5.  Protease inhibitor reduces airway response and underlying inflammation in cockroach allergen-induced murine model.

Authors:  Sanjay Saw; Naveen Arora
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

Review 6.  Zoonotic parasites carried by invasive alien species in China.

Authors:  Guang-Li Zhu; Yi-Yang Tang; Yanin Limpanont; Zhong-Dao Wu; Jian Li; Zhi-Yue Lv
Journal:  Infect Dis Poverty       Date:  2019-01-09       Impact factor: 4.520

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.